SCNI

Scinai Immunotherapeutics Ltd. SCNI

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$1.31M

Quarter to Dec 31

Net income

$-8.31M

Quarter to Dec 31

Free cash flow

$-6.05M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$46.1K total
CITADEL ADVISORS LLC
$15.7KNew
ARMISTICE CAPITAL, LLC
$9.1KNew
Virtu Financial LLC
$5.0KNew
StoneX Group Inc.
$4.6KNew
XTX Topco Ltd
$4.2K-30.3%
RHUMBLINE ADVISERS
$3.4K+619.5%
CAPTRUST FINANCIAL ADVISORS
$3.0KNew
UBS Group AG
$1.0K+330.4%
MORGAN STANLEY
$150.0%
HRT FINANCIAL LP
$3New
ROYAL BANK OF CANADA
$0New
See all 11 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SCNI

Earnings Per Share

13fpro.ai/company/SCNI

Loading ratio trend…

SCNI key financials by period

Reported revenue, net income and operating margin by fiscal year, from Scinai Immunotherapeutics Ltd.'s annual filings on SEC EDGAR.

Scinai Immunotherapeutics Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.3M$-8.3M—
FY 2024$658.0K$4.8M—
Source: SCNI filings on SEC EDGAR →

SCNI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Scinai Immunotherapeutics Ltd. (SCNI): stock profile, AI score and financials

Scinai Immunotherapeutics Ltd. (SCNI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SCNI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Scinai Immunotherapeutics Ltd. reports quarterly revenue of $1.3M, net income of $-8.3M, free cash flow of $-6.1M. Top institutional holders of SCNI by reported 13-F value include CITADEL ADVISORS, ARMISTICE CAPITAL, Virtu Financial, based on the most recent SEC filings. SCNI trades on the Nasdaq exchange and files with the SEC under CIK 1611747. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCNI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Scinai Immunotherapeutics Ltd. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1611747 →